Thun

Researchers are evaluating sacituzumab tirumotecan alone and combined with pembrolizumab compared to the treatment chosen by a physician for people with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer that cannot be removed by surgery or has spread to other parts of the body. This study focuses on participants whose cancer has progressed despite prior endocrine therapy, including treatment with a CDK4/6 inhibitor. The main goal is to see if these treatments improve progression-free survival, which means the length of time the cancer does not worsen, over up to approximately 38 months. Participants receive sacituzumab tirumotecan as an intravenous infusion, either alone or combined with intravenous pembrolizumab. The comparison group receives the treatment of physician's choice, which may include intravenous paclitaxel, nab-paclitaxel, liposomal doxorubicin, or oral capecitabine. The study is open-label and randomized, meaning participants are assigned to different treatment groups openly. Treatments are administered according to the study protocols, with ongoing monitoring during the treatment period. Throughout the study, participants are monitored regularly to assess their cancer status and overall health. This includes evaluations by blinded independent central review using RECIST 1.1 criteria to measure tumor progression. Researchers also assess safety, organ function, and performance status. The total participation time may last up to around 38 months to track progression-free survival and other outcomes. Careful monitoring helps ensure participant safety and collects data on treatment effectiveness and side effects.

This trial investigates the effectiveness of Pumitamig compared to Pembrolizumab in adults with advanced Non-Small Cell Lung Cancer (NSCLC) who have not received prior treatment and whose tumors express PD-L1 at 50% or higher. The study targets individuals with locally advanced or metastatic NSCLC, focusing on those with measurable disease and good performance status. It is a Phase 3 randomized, double-blind study designed to compare these two treatments as first-line options for this patient group. Participants will receive either Pumitamig or Pembrolizumab at specified doses on scheduled days. The treatments are given as monotherapy, meaning each participant receives only one of these drugs throughout the study. The study does not mention additional treatment phases or extensions, focusing on the direct comparison of these two drugs for initial treatment. Throughout the study, researchers will assess how long participants live without their cancer worsening, using standardized criteria over about three years. Overall survival will also be tracked for up to five years. Participants will be monitored regularly to evaluate their response to treatment and overall health. Safety and effectiveness outcomes will be gathered through medical assessments consistent with clinical trial standards for NSCLC.

Chronic leg and foot ulcers are wounds that do not heal properly over several weeks, often due to blood flow problems caused by conditions like chronic venous insufficiency or peripheral artery disease. These ulcers share biological challenges such as reduced oxygen and nutrient supply, leading to impaired cell functions, persistent inflammation, and infections that prevent healing. Standard treatments include compression therapy, physical activity, and surgical procedures to improve blood flow and support wound repair. This trial evaluates a combined treatment called Concurrent Optical and Magnetic Stimulation (COMS) alongside standard care, compared to standard care alone, in patients with venous leg ulcers or venous leg ulcers with peripheral artery disease. COMS therapy uses magnetic stimulation and light therapy to activate cellular processes that promote healing, such as increased energy production, cell growth, blood vessel dilation, and reduced inflammation. Patients in the intervention group receive COMS treatment 2-3 times weekly for at least 8 weeks, with a minimum of 16 sessions, during their usual wound care procedures. Participants will be followed for a total of 24 weeks. During this time, researchers will monitor wound healing progress, including the percent reduction in wound area at 24 weeks. Assessments include wound evaluations, quality of life measures, pain levels, and device usability. The study is conducted across multiple centers in several European countries, with treatments and follow-up occurring in outpatient or home care settings. Safety and effectiveness data will be analyzed to understand the impact of COMS therapy on chronic vascular ulcers.

Researchers are studying the effects of continued nutritional support after hospital discharge for adult medical patients who are at nutritional risk due to malnutrition. This research aims to compare ongoing post-discharge nutritional support to usual care home nutrition and assess its impact on mortality, frailty, functional outcomes, and recovery. The study builds on earlier findings that nutritional support during hospital stays reduces complications and mortality, but long-term benefits after discharge remain unclear. Participants receive individualized nutritional plans supervised by experienced dietitians, including the daily use of specific oral nutritional supplements with high energy and protein content such as Resource Ultra and Resource 2.0 (Fibre). The plan may be adjusted based on patient preferences, including options like between meal snacking and food enrichment. General nutritional information about healthy food behavior is also provided upon hospital discharge. Follow-up phone calls occur every 2 to 4 weeks to monitor and support adherence to the nutritional intervention. During the study, participants are closely monitored for outcomes including time to death from any cause over a three-year period. Researchers will evaluate frailty, functional recovery, and overall health status. The study involves ongoing assessments and follow-ups to understand how long-term nutritional support influences disease progression and recovery. Participants' adherence to the nutritional plans is supported and tracked through regular dietitian contact and supplement use.

Researchers are evaluating treatment strategies for older and frail patients aged 70 and above with metastatic non-small cell lung cancer (NSCLC) who have PD-L1 expression less than 50%. This phase II trial compares the safety and effectiveness of reduced-dose chemotherapy combined with cemiplimab versus cemiplimab alone. The study addresses the challenge that standard full-dose chemotherapy often causes severe side effects in elderly or frail patients, aiming to find a better-tolerated treatment option that maintains cancer control. Participants are randomly assigned to receive either reduced-dose platinum-doublet chemotherapy with cemiplimab or cemiplimab monotherapy. Chemotherapy drugs include carboplatin at a lower dose (AUC 3), combined with pemetrexed and gemcitabine or paclitaxel, given intravenously on specific days. Cemiplimab is administered as an IV infusion every three weeks and continued for up to two years or until disease progression or unacceptable side effects. Patients who progress on monotherapy may switch to the combination treatment if suitable. Throughout the study, patients undergo regular imaging scans every 6 to 12 weeks to monitor tumor response and disease progression. Quality of life questionnaires and geriatric assessments, including hand-grip strength and mobility tests, are conducted at defined intervals. Researchers measure progression-free survival over one year and overall survival, along with side effects, patient-reported treatment acceptability, and overall treatment benefit. The total sample size is approximately 156 patients across multiple sites in Switzerland.

Researchers are evaluating the safety and effectiveness of adding sacituzumab tirumotecan to pembrolizumab compared to the treatment of physician's choice in adults with triple-negative breast cancer (TNBC) who received neoadjuvant therapy but did not achieve a complete response after surgery. This Phase 3, randomized, open-label study aims to determine if the combination improves invasive disease-free survival (iDFS) over other approved treatments. The study focuses on participants who have residual disease after surgery and have recovered sufficiently to continue treatment. Participants receive either sacituzumab tirumotecan 4 mg/kg intravenously every two weeks combined with pembrolizumab 400 mg intravenously every six weeks, or treatment chosen by their physician, which may include pembrolizumab alone or pembrolizumab with oral capecitabine taken twice daily. Treatment is given after surgery and any indicated radiation therapy, with randomization occurring within 16 weeks post-surgery. The study monitors participants for up to about 77 months to assess long-term outcomes. During the study, participants undergo regular assessments including clinical evaluations and monitoring for disease recurrence, side effects, and overall health. Tissue samples collected at surgery are analyzed for biomarkers like TROP2. Safety is closely monitored, and participants must have good performance status to join. The study collects data on how long participants remain disease-free and tracks any adverse events to understand treatment effects over the extended follow-up period.

Researchers are studying the use of venetoclax in people with chronic lymphocytic leukemia (CLL) to understand how effective it is and to assess the costs and patient-reported outcomes when used in real-life medical settings. The study looks at venetoclax given alone or combined with rituximab, obinutuzumab, ibrutinib, or acalabrutinib, based on doctors' decisions and local treatment guidelines. Participants receive venetoclax therapy as prescribed by their physician, which may include the drug alone or along with one of the mentioned combination treatments. The study follows patients in Austria, Germany, and Switzerland, observing how the treatments are used in everyday practice without altering the prescribed therapy. During the study, participants are monitored for up to 12 months to measure the percentage who achieve the best overall response rate (ORR) to treatment. Researchers also collect data on health economics and patient experiences to better understand the impact of these therapies in routine care.

Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs) are rare tumors that arise from the neuroendocrine system in the gastrointestinal tract and pancreas. This registry study aims to better understand these tumors by collecting detailed clinical information from patients diagnosed with GEP-NETs in Switzerland. Since limited knowledge exists about the biology and treatment of these tumors, the study focuses on gathering data to improve understanding and management strategies. Patients with a confirmed diagnosis of neuroendocrine tumors from any location who agree to participate will have their information entered prospectively into a secure, anonymized database. Data collection involves visits from study nurses to healthcare centers, where patient files are reviewed and information is recorded. There are no specific treatments assigned by this registry; instead, it tracks various treatment approaches used in Switzerland. Participants contribute data that includes tumor types, treatments received, and outcomes such as mortality and hospitalization rates. The study reviews and evaluates this information regularly to identify patterns and assess patient outcomes over time. The main outcome measured is tumor-related mortality every five years, helping to monitor long-term effects. This registry allows for improved knowledge sharing across hospitals and practitioners in Switzerland to enhance care for patients with neuroendocrine tumors.

The main aims of the study will be: 1. To obtain epidemiological data on individuals asking for PrEP in Switzerland. We are particularly interested in: * Determining the extent of PrEP use in Switzerland; * Assessing and monitoring the occurrence of sexually transmitted infections (STIs) in this particular population. 2. To assess sexual health and sexual well-being in individuals asking for PrEP using a questionnaire specifically designed for the SwissPrEPared program.